Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ropivacaine + tramadol
- Development stage
- Unknown
- Lead developer
- Aga Khan University
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Ropivacaine + tramadol is a combination analgesic therapy being investigated by Aga Khan University for the management of postoperative pain, specifically following Video-Assisted Thoracoscopic Surgery (VATS). Ropivacaine is a long-acting amide-type local anesthetic that works by blocking sodium channels, thereby inhibiting nerve impulse conduction. Tramadol is a centrally acting synthetic opioid analgesic with a dual mechanism of action: it acts as a mu-opioid receptor agonist and also inhibits the reuptake of norepinephrine and serotonin. In this specific application, the combination is administered via subcutaneous wound infiltration to provide localized pain relief and reduce the need for systemic opioids. The combination aims to leverage the synergistic effects of local anesthesia and centrally acting analgesia to improve postoperative recovery.
- Other names
- ropivacaine + tramadol-Aga Khan University-postoperative painRopivacaine and tramadol combinationRopivacaine + Tramadol
02
Targets
SERT (Sodium-dependent serotonin transporter)NaV (Voltage-gated sodium channels)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on ropivacaine + tramadol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ropivacaine + tramadol.